Title : Mometasone furoate nasal spray on recovery of long-term olfactory dysfunction due to COVID-19: A systematic review and meta-analysis of a randomized controlled trials
Abstract:
PubMed, Cochrane, and Embase databases were searched for RCTs. Data were extracted from published reports, and quality assessment was performed according to PRISMA guidelines. We used a fixed-effect model to calculate the risk ratio (RR) and the 95% confidence interval (CI). Endpoints of interest were: recovery of olfactory dysfunction, with partial or full response.
This review's protocol was registered at PROSPERO, under the number CRD42022382930. Four RCTs studies were included with a total of 340 participants, of whom 146 (42,9%) were randomized to receive mometasone furoate nasal spray. These participants on average had persistent anosmia or severe microsmia for more than 3 weeks. Completely recovered sense of smell (RR 1.47; CI 95% 1.17-1.84; p = 0.001; I2 = 24%; Figure 1) was significantly higher in patients treated with mometasone furoate nasal spray compared with the control group.
Partial or fully recovered from anosmia (RR 1.53; CI 95% 1.19-1.96; p = 0.0009; I2 = 3%; Figure 2) was also significantly increased in the mometasone furoate nasal spray group when compared to the control group. Our meta-analysis suggests that mometasone furoate nasal spray is effective in the recovery of longterm olfactory dysfunction due to COVID-19.
Audience Take Away:
- Several patients have reported persistent olfactory dysfunction after recovering from COVID- 19.
- We performed a systematic review and meta–analysis of randomized controlled trials (RCTs) to evaluate the efficacy of mometasone furoate nasal spray for long-term olfactory dysfunction due to COVID-19.
